tbuckley/cabot-search huggingface dataset:
Phase II neoadjuvant docetaxel/cisplatin followed by concurrent cisplatin/radiotherapy for locally advanced nasopharyngeal cancer
Authors: M. S. Kandil, H. S. Alnasser, S. A. Bandey, A. S. Almutairy, F. A. Ammar, A. A. Saadeddin, E. M. Murshid, M. A. Asiri, A. M. Zahrani
Journal: Journal of Clinical Oncology (2007)

6059 Background: Neoadjuvant cisplatin/docetaxel are active agents for locally advanced nasopharyngeal cancer (LANPXCA). The efficacy and tolerability of neoadjuvant cisplatin/docetaxel followed by concurrent cisplatin with radiotherapy are explored in a phase II trial. Methods: From Jan 2003 to Jan 2005; 23 patients with LANPXCA stage III, IVA, IVB, (AJCC 2002), were treated with 3 cycles of neoadjuvant docetaxel 60mg/m 2 , 1 hour IV infusion D1 and cisplatin 60 mg/m 2 , 2 hours IV infusion D1 with prophylactic GSCF as 5μg/kg sc D3–7,(recycle D22). This was followed by 2 cycles of cisplatin 100 mg/m 2 , 2 hours IV infusion D1 , (recycle D22), concurrently with radiotherapy aiming at 70Gy / 35 fractions / 7 weeks. The median follow up was 27.9 months (18.3–47.3). Results: The median age was 38 years (16–68) and male to female ratio was 7.66:1. Neck mass 95.7%, neck pain 73.9%, nasal obstruction 65.2%, , headache 56.5%, impaired hearing 52.2%, and epistaxis 52.2% were the commonest symptoms. All patients had G3 squamous cell carcinoma. The majority of patients were stage IV 52.2% while 47.8 % were stage III. Grade one ECOG performance status was the commonest 52.2% while 47.8% were G2. The treatment was tolerable with commonest G3 acute toxicities were dysphagia 43.4% , and oral mucositis 8.7%. The commonest G3 late toxicities were dry mouth 17.4% and impaired hearing 13%. Complete remission was achieved in 22/23 patients 95.7% while 1/23 patients 4.3% was partial responder. Failure sites include; Distant; liver and/or bone 8.7%, local; skull base 4.3% or local and distant 4.3%.The Kaplan Meyer 47 month disease free survival was 82.61% while the 47 month overall survival was 91.3%. Conclusion: Neoadjuvant docetaxel / cisplatin followed by concurrent Cisplatin with radiotherapy is an effective and tolerable outpatient treatment for LANPXCA. No significant financial relationships to disclose.
Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer.
Authors: Sangeetha Meda Reddy, Maureen Sadim, Irene B. Helenowski, Jun Li, Nengjun Yi, Virginia G. Kaklamani
Journal: Journal of Clinical Oncology (2012)

1561 Background: Obesity and weight gain in breast cancer patients has been associated with decreased quality of life, decreased response to chemotherapy, increased cancer recurrence, and higher all-cause mortality. Our study was designed to identify factors that contribute to this weight gain. Methods: Chart review was conducted on 565 breast cancer patients to obtain weights and BMIs over an 18 month period from diagnosis, tumor characteristics (ER/PR/Her2 status, grade, presence of LN metastases, stage), demographics (age, race), clinical factors (menopausal status), and treatment regimens (chemotherapy, hormone therapy, radiation). Blood samples were genotyped for polymorphisms in FTO (fat mass and obesity-associated protein) and the adiponectin pathway, two pathways found to be associated with obesity and breast cancer risk. Results: See table. For genetic analysis, one statistically significant epistatic and three gene x environmental interactions were detected for adiponectin SNPs: rs822396d x BMI at diagnosis (effect size 8.65), rs2232853a x age (2.75), rs1501299a x BMI at diagnosis (3.63), and rs266729d x rs7539542d (6.40). Conclusions: We have identified multiple clinical and genetic variables that are likely predictors of weight gain in breast cancer patients. We are conducting a prospective study of 200 breast cancer patients to validate the findings of this retrospective study. By identifying a high risk patient population, we hope to target them for aggressive lifestyle interventions to prevent weight gain and thereby improve their mortality and morbidity. [Table: see text]
Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
Authors: Rafal Panek, Liam Welsh, Lauren C.J. Baker, Maria A. Schmidt, Kee H. Wong, Angela M. Riddell, Dow-Mu Koh, Alex Dunlop, Dualta Mcquaid, James A. d'Arcy, Shreerang A. Bhide, Kevin J. Harrington, Christopher M. Nutting, Georgina Hopkinson, Cheryl Richardson, Carol Box, Suzanne A. Eccles, Martin O. Leach, Simon P. Robinson, Kate L. Newbold
Journal: Clinical Cancer Research (2017)

Abstract Purpose: To evaluate intrinsic susceptibility (IS) MRI for the identification of cycling hypoxia, and the assessment of its extent and spatial distribution, in head and neck squamous cell carcinoma (HNSCC) xenografts and patients. Experimental Design: Quantitation of the transverse relaxation rate, R2*, which is sensitive to paramagnetic deoxyhemoglobin, using serial IS-MRI acquisitions, was used to monitor temporal oscillations in levels of paramagnetic deoxyhemoglobin in human CALR xenografts and patients with HNSCC at 3T. Autocovariance and power spectrum analysis of variations in R2* was performed for each imaged voxel, to assess statistical significance and frequencies of cycling changes in tumor blood oxygenation. Pathologic correlates with tumor perfusion (Hoechst 33342), hypoxia (pimonidazole), and vascular density (CD31) were sought in the xenografts, and dynamic contrast-enhanced (DCE) MRI was used to assess patient tumor vascularization. The prevalence of fluctuations within patient tumors, DCE parameters, and treatment outcome were reported. Results: Spontaneous R2* fluctuations with a median periodicity of 15 minutes were detected in both xenografts and patient tumors. Spatially, these fluctuations were predominantly associated with regions of heterogeneous perfusion and hypoxia in the CALR xenografts. In patients, R2* fluctuations spatially correlated with regions of lymph nodes with low Ktrans values, typically in the vicinity of necrotic cores. Conclusions: IS-MRI can be used to monitor variations in levels of paramagnetic deoxyhemoglobin, associated with cycling hypoxia. The presence of such fluctuations may be linked with impaired tumor vasculature, the presence of which may impact treatment outcome. Clin Cancer Res; 23(15); 4233–41. ©2017 AACR.
Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism
Authors: C. M. Taniguchi
Journal: Journal of Clinical Investigation (2005)

Due to an error in manuscript preparation, an incorrect shRNA sequence for IRS2 was published.The correct hairpin sequence is a 19-nt stretch beginning from nt 703 of the published IRS2 cDNA sequence (XM_357863).The oligonucleotides cloned into the U6 construct for the IRS2U6 adenovirus are as follows: tcgagGTGACGCTGCAGCTTATGAttcaagagaTCATAAGCTGCAGCGTCACttttt (forward) and ctagAAAAAGTGACGCTGCAGCTTATGAtctcttgaaTCATAAGCTGCAGCGTCACc (reverse).In addition, the shRNA cassettes were cloned into the adenoviral cosmid pAxcwit, which lacks a promoter, and not the cosmid pAxCAwtit, as published..
ASSOCIATION OF CORONARY CALCIUM, CAROTID WALL THICKNESS AND CAROTID PLAQUE PROGRESSION WITH LOW DENSITY LIPOPROTEIN AND HIGH DENSITY LIPOPROTEIN PARTICLE CONCENTRATION MEASURED BY ION MOBILITY TESTING: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
Authors: Indre Ceponiene, Samar El Khoudary, Dong Li, James Stein, Nathan Wong, Rine Nakanishi, Negin Nezarat, Mitsuru Kanisawa, Sina Rahmani, Kazuhiro Osawa, Matthew Tattersall, Matthew Budoff
Journal: Journal of the American College of Cardiology (2017)
Predictors of General Discomfort, Limitations in Activities of Daily Living, and Intention of a Second Donation in Unrelated Hematopoietic Stem Cell Donation
Authors: Mark Lee, Jin Ho Jang, Hyo Jin Min, Hyung In Jang, Jung Hwa Nah, Chuhl Joo Lyu, Kyou Sup Han, Jong-Ho Won, Young Ho Lee, So Young Chong, Yeung Chul Mun, Won Sik Lee, Seok Jin Kim, Inho Kim
Journal: Blood (2016)
Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice
Authors: Ivana De Domenico, Tian Y. Zhang, Curry L. Koening, Ryan W. Branch, Nyall London, Eric Lo, Raymond A. Daynes, James P. Kushner, Dean Li, Diane M. Ward, Jerry Kaplan
Journal: Journal of Clinical Investigation (2012)
CAROTID PLAQUE AREA IS INCREASED IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DYSGLYCEMIA
Authors: Thorarinn Arni Bjarnason, Steinar Hafthorsson, Linda Kristinsdottir, Erna Óskarsdóttir, Thor Aspelund, Sigurdur Sigurdsson, Vilmundur Gudnason, Karl Andersen
Journal: Journal of the American College of Cardiology (2017)
Antroquinonol to block Ras and Rho signaling via the inhibition of protein isoprenyltransferase activity in cancer cells.
Authors: Ching-Liang Ho, Howard Cheng, Miles Chih-Ming Chen, David S. Ettinger
Journal: Journal of Clinical Oncology (2015)

e18526 Background: Antroquinonol is the smallest anticancer molecule isolated from Antrodia camphorata thus far. The ubiquinone-like structure of Antroquinonol exhibits a broad spectrum of activity against malignancies in vivo and in vitro. However, the mechanism of action of Antroquinonol remains unclear. Methods: Cytotoxicity effect of Antroquinonol on several human cell lines were demonstrated. Effect of Antroquinonol on Ras processing and ERK phosphorylation were detected by Western blotting. In-gel fluorescence analysis was conducted to determine the levels of prenylated Ras. The interaction between Antroquinonol and FTase was predicted by molecular docking algorithm. Results: We found that the inactive forms of Ras and Rho proteins were significantly elevated in cancer cells after treatment with Antroquinonol. We also demonstrated that Antroquinonol binds directly to farnesyltransferase (FTase) and geranylgeranyltransferase-I, which are key enzymes involved in activation of Ras-related proteins, and inhibits enzymes activities in vitro. Furthermore, a molecular docking analysis illustrated that the isoprenoid moiety of Antroquinonol binds along the hydrophobic cavity of FTase similar to its natural substrate, farnesyl pyrophosphate. In contrast, the ring structure of Antroquinonol lies adjacent to the Ras-CAAX motif binding site on FTase. The molecular docking study also showed a reasonable correlation with the IC50values of Antroquinonol analogues. We also found that the levels of LC3B-II and the autophagosome-associated LC3 form were also significantly increased in H838 after Antroquinonol administration. Conclusions: Antroquinonol inhibited Ras and Ras-related GTP-binding protein activation through inhibition of protein isoprenyl transferase activity, leading to activation of autophagy and associated mode of cell death in cancer cells. The natural origin of Antroquinonol is now undergoing Phase 2 clinical evaluation in patients with non-small cell lung cancer. Understanding the mechanism of action of Antroquinonol will facilitate the identification of predictive biomarkers and will aid in the rational design of future clinical trials. Clinical trial information: NCT02047344.
Outcome of patients with nonmetastatic, muscle-invasive bladder cancer (MIBC), not undergoing cystectomy, after treatment with non-cisplatin-based chemotherapy and/or radiotherapy: A retrospective analysis.
Authors: Aristotelis Bamias, Petros Tsantoulis, Thomas Zilli, Konstantinos Koutsoukos, Francesca Caparrotti, Michael Liontos, Arnaud Roth, Maria Lykka, Kostas Stravodimos, Michael Chrisofos, Athanasios Papatsoris, Eleni Efstathiou, Gregory J Wirth, Dionysios Mitropoulos, Constantinos A Constantinides, Charalambos Deliveliotis, Christophe E Iselin, Raymond Miralbell, Pierre-Yves Dietrich, Meletios A. Dimopoulos
Journal: Journal of Clinical Oncology (2013)

e15619 Background: Τransurethral resection of bladder tumor (TURBT), radiotherapy, chemotherapy or combinations can be used in patients with MIBC not undergoing cystectomy, but the optimal treatment is yet unknown. Cisplatin-based chemotherapy is the standard if systemic therapy is to be used. Nevertheless, unfitness for cystectomy is frequently associated with unfitness-for-cisplatin. We report the outcome of patients with MIBC who did not undergo cystectomy and did not receive cisplatin-based chemotherapy. Methods: Selection criteria: non-metastatic MIBC, no cystectomy, no cisplatin-based chemotherapy. Chemotherapy and/or radiotherapy should have been used apart from TURBT. Unfitness for Cisplatin was determined by: creatinine clearance &lt; 50 ml/min, PS &gt; 2, hearing loss, co-morbidities precluding adequate hydration. Carboplatin/gemcitabine was used in patients receiving chemotherapy. Tumor extent was evaluated by TURBT and CT. Patients consented to the use of their data. Results: 49 patients (median age 79), managed between 2/2003-2/2012 were included in this analysis (Table 1). 40 patients (82%) had T2 tumors. No factor for unfitness-for-cisplatin was present in 4 cases. During a median fup of 68 months 29 patients died (5 not due to disease). Treatment after TURBT and outcome are shown in the Table. Conclusions: Most patients with non-metastatic MIBC, not undergoing cystectomy, are also unfit-for-cisplatin, although comorbidities used as unfitness criteria do not always adhere to current guidelines. The outcome of these patients is poorer than that expected with cystectomy. Combining chemotherapy with radiotherapy produced numerically better outcomes and should be prospectively evaluated. [Table: see text]
Ibrutinib in Association with R-DHAP/Ox for Patients with Relapsed/Refractory B-Cell Lymphoma: Preliminary Results of the Biblos Phase Ib Lysa Study
Authors: Christophe Bonnet, Thierry Lamy, Christophe Fruchart, Steven Le Gouill, Katharina Gunzer, Thomas Gastinne, Fabrice Jardin, Lionel Karlin, Roch Houot, Jehan Dupuis, Hervé Tilly, Gilles A. Salles
Journal: Blood (2016)
THE ASSOCIATION OF HIGH RISK PLAQUE FEATURES AND NON-INVASIVE FRACTIONAL FLOW RESERVE DERIVED FROM CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY IN PATIENTS WITH ACUTE CHEST PAIN: RESULTS FROM THE ROMICAT II TRIAL
Authors: Maros Ferencik, Michael T. Lu, Thomas Mayrhofer, Stefan B. Puchner, Ting Liu, Pal Maurovich-Horvat, Alexander Ivanov, Elizabeth Adami, Brian Ghoshhajra, Souma Sengupta, Campbell Rogers, Udo Hoffmann
Journal: Journal of the American College of Cardiology (2017)
Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Authors: Heike Pfeifer, B. Wassmann, Wolfgang A. Bethge, Jolanta Dengler, Martin Bornhäuser, Michael Stadler, Dietrich Beelen, Andreas Günther, Vladan Vucinic, Thomas Burmeister, Matthias Stelljes, Rainer Schwerdtfeger, Kerstin Schaefer-Eckhart, Peter Bader, Hermann Kreyenberg, Peter Schuld, Hubert Serve, Dieter Hoelzer, Nicola Goekbuget, Oliver G. Ottmann
Journal: Blood (2011)
Evidence-based tumor response assessment with imaging in bone metastases from breast cancer
Authors: T. Hamaoka, C. M. Costelloe, J. E. Madewell, G. N. Hortobagyi, N. T. Ueno
Journal: Journal of Clinical Oncology (2004)

840 Background: Bone is the most common site of breast cancer metastasis, but no consensus has been reached as to the best way to image bone lesions to assess their response to treatment. Criteria for bone tumor response (UICC, WHO) are based on plain radiography (XR) and skeletal scintigraphy (SS), which both take up to 6 months to reveal responses; however, oncologists tended to use CT, MRI, or PET in recent years for this purpose. A new algorithm is needed for accurate, reliable and earlier assessment of bone tumor response. Methods: We searched MEDLINE (1966–2003) for English-language peer-reviewed articles on means of detecting and monitoring bone metastasis from breast cancer with the combinations of search terms (e.g., skeleton, breast neoplasms), which identified 2,367 papers. Of these, we selected 328 papers related to imaging of bone metastasis from breast cancer, analyzed the data using NCI guidelines to evaluate the level of evidence, and attempted to generate recommendations for which imaging modality is best for assessing bone tumor response to treatment. Results: Surprisingly, there were very few peer-reviewed papers focused on bone tumor response assessment in metastatic breast cancer. Of 28 papers identified and available, 22 were evidence level II, 5 were level III, and 1 was level IV. Only 1 paper included measures of sensitivity (XR 91%, SS 57%). CT can show structural changes in trabecular and cortical bone. MRI is excellent for assessment of intramedullary lesions but is less able to assess cortical bone. XR is inexpensive but requires greater than 30% cortical loss to be detected, while SS can generate whole-body images but “flares” reduce its sensitivity and specificity. There is very limited data for use of PET. Conclusions: CT may be the best modality for assessing tumor responses in cortical bone. However data on sensitivity is too limited to support changing current clinical practice. We will present an algorithm for an evidence-based tumor response assessment based on imaging of bone metastases in breast cancer patients at the upcoming meeting. Prospective analysis is needed to generate a new evidence-based algorithm using CT, MRI, and/or PET. No significant financial relationships to disclose.
The BMJ Awards 2017: Imaging
Authors: Nigel Hawkes
Journal: BMJ (2017)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following The BMJ Awards 2017: Imaging Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
ELEVATED MYOCARDIAL EXTRACELLULAR VOLUME FRACTION (ECV) AND ITS PROGNOSTIC SIGNIFICANCE IN DIABETIC INDIVIDUALS
Authors: Mohammad Khan, Eric Yang, Mohamad Ghosn, Faisal Nabi, Stephen Pickett, Patrick Green, David Aguilar, William Zoghbi, Sherif Nagueh, Dipan Shah
Journal: Journal of the American College of Cardiology (2017)
Antagonist Anti-CD40 Antibody, CHIR-12.12, Induces ADCC, Inhibits Tumor Growth, and Prolongs Survival in a Human Multiple Myeloma Xenograft Model.
Authors: Li Long, Xia Tong, Montesa Patawaran, Sharon L. Aukerman, Bahija Jallal, Mohammad Luqman
Journal: Blood (2005)
PREVALENCE AND PREDICTORS OF PACEMAKER PLACEMENT IN ADULT FONTAN PATIENTS
Authors: Anushree Agarwal, Aarthi Sabanayagam, Ahmed Kheiwa, Colin Cunnington, Edward Gerstenfeld, Charles McCulloch, Ian Harris, Zian Tseng, Elyse Foster, Petra Jenkins, Jaspal Dua, Devinda Karunaratne, Sahrkaw Muhyaldeen, Amir Zaidi, Adam Fitzpatrick, Clifford Garratt, Bernard Clarke, Andreas Hoschtitzky, Vaikom Mahadevan
Journal: Journal of the American College of Cardiology (2017)
MINERALOCORTICOID RECEPTOR ANTAGONISTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS
Authors: Matthias Bossard, Yasser Binbraik, Farzin Beygui, Bertram Pitt, Faiez Zannad, Gilles Montalescot, Sanjit Jolly
Journal: Journal of the American College of Cardiology (2017)
The Production of Vascular Endothelial Growth Factor Is Decreased in Acute Myelogenous Leukemia Cases That Are Treated with Chemotherapeutic Agents and Show the Prolonged Bone Marrow Suppression.
Authors: Haruko Tashiro, Mitsuho Noguchi, Ryosuke Shirasaki, Kazuo Kawasugi, Naoki Shirafuji
Journal: Blood (2007)
A study to identify incidence of ROS1 rearrangement in lung adenocarcinoma, cholangiocarcinoma and glioblastoma multiforme.
Authors: Sun Min Lim, Jeong Eun Yoo, Hyo Sup Shim, SE Hoon KIM, Young Nyun PARK, Byoung Chul Cho
Journal: Journal of Clinical Oncology (2015)

e22203 Background: In this study, we aimed to identify incidence and clinicopathologic features of ROS1 rearrangement in LADC, cholangiocarcinoma (CCA) and glioblastoma multiforme (GBM), which were previously reported to harbor ROS1 rearrangement. Methods: We prospectively collected pathologically proven LADC, CCA and GBM patients. Eligible patients had an adequate quantity and quality of formalin-fixed paraffin-embedded tumor for analysis and available clinical, demographic, pathologic data. A total of 500 LADC, 261 CCA and 99 GBM consecutive samples were included. Fluorescent in situ hybridization (FISH) assays were carried out by using a break-apart probe to ROS1. Results: We identified that 5.2% (n = 26) of LADC and 1.1% (n = 3) of CCA had ROS1 rearrangements. ROS1 rearrangement was not identified in GBM patients. ROS1 rearrangement was mutually exclusive with EGFR mutation (n = 155), KRAS mutation (n = 26) and ALK-fusion (n = 31). ROS1 fusion-positive LADC had poorer recurrence-free survival (RFS) than fusion-negative patients (median RFS, 9.0 vs. 14.7 months; P = 0.015). There was also a significant RFS difference in pair-wise comparison of four genotypes. The median RFS was 32.1 vs. 6.3 vs. 11.9 vs. 9.0 months for EGFR mutant, KRAS mutant, ALK-fusion and ROS1-fusion group, respectively (P = 0.006). When ROS1-fusion was compared with three other molecular subtypes, there was a statistically significant difference in OS by log-rank test (26.1 vs. 9.1 vs. 14.9 vs. 12.8 months, P = 0.009). In a Cox-regression analysis, adjusting for age, gender, stage, and mutation, the HR risk of recurrence was 2.753 (P = 0.037) and the HR for the risk of death was 3.543 (P = 0.008) for patients with ROS1 rearrangement. Three cases showing ROS1-positivity among CCA were all intrahepatic origin (1.4% of intrahepatic CCA). There were 1 mass-forming, 1 intraductal growth and 1 periductal infiltrating type. Among three ROS1-positive patients, one patient was treated with crizotinib and the patient maintained stable disease for three months with minimal tumor shrinkage (-8.5%). Conclusions: In this study, we identified that ROS1 rearrangement defines a rare, but distinct molecular subgroup in LADC and CCA.
OUTCOMES OF PCI VERSUS CABG IN LEFT MAIN DISEASE ACCORDING TO SYNTAX SCORE BY SITE VERSUS ANGIOGRAPHIC CORE LABORATORY ASSESSMENT: INSIGHTS FROM THE EXCEL TRIAL
Authors: Philippe Genereux, Patrick Serruys, A. Kappetein, Ad Van Boven, Mark Hickey, David Kandzari, Erick Schampaert, Ferenc Horkay, Imre Ungi, Samer Mansour, Stuart Pocock, Adrian Banning, David Taggart, Manel Sabate, Anthony Gershlick, Piet Boonstra, Nicholas Lembo, John Puskas, Ioanna Kosmidou, W. Morris Brown, Roxana Mehran, Ori Ben-Yehuda, Charles Simonton, Joseph Sabik, Gregg Stone
Journal: Journal of the American College of Cardiology (2017)
CONTEMPORARY PATTERNS OF GP IIB/IIIA INHIBITOR USE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION UNDERGOING PCI: INSIGHTS FROM THE TRANSLATE ACS STUDY
Authors: Homam Ibrahim, Lisa McCoy, Connie Hess, Mohammed Akhter, Mark Effron, Gregg Stone, Tracy Wang
Journal: Journal of the American College of Cardiology (2017)
Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma
Authors: Sandra Susanibar, Victoria Carlton, Sharmilan Thanendrarajan, Meera Mohan, Pankaj Mathur, Shadiqul Hoque, Muthukumar Radhakrishnan, Frits van Rhee, Maurizio Zangari, Faith E Davies, Katherine A. Kong, Gareth J Morgan, Daisy V. Alapat, Carolina Schinke
Journal: Blood (2016)
EFFECT OF PULMONARY PRESSURE MONITORING (CARDIOMEMS HEART FAILURE SYSTEM, ST. JUDE MEDICAL) ON HOSPITAL ADMISSIONS AND EMERGENCY DEPARTMENT VISITS: A MULTICENTER REAL WORLD EXPERIENCE
Authors: Daniel Davidovich, Orvar Jonsson, Jamie Pelzel, Mosi Bennett, Bradley Bart, Shari A. Mackedanz, Anne Sexter
Journal: Journal of the American College of Cardiology (2017)
ACUTE AORTIC DISSECTION IN PATIENTS WITHOUT A HISTORY OF HYPERTENSION
Authors: Artur Evangelista Masip, Patrick O'Gara, Mark Peterson, Dan Gilon, Stuart Hutchison, Kevin Harris, Marc Bonaca, Anil Bhan, Emil Missov, T. Brett Reece, Khaled Abdul-Nour, Daniel Montgomery, Kim Eagle, Christoph Nienaber, Eric Isselbacher, Eduardo Bossone
Journal: Journal of the American College of Cardiology (2017)